Genentech, a member of the Roche (RHHBY) Group, announced plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs, NC. The project will add more than 400 high-wage manufacturing jobs when the site is operational and more than 1,500 construction jobs during site development. The new facility will ultimately support Roche and Genentech’s future portfolio of next-generation obesity medicines and this initial investment could expand in the future based on business needs and the U.S. policy environment. Roche and Genentech’s current U.S. footprint includes 13 manufacturing and 15 R&D sites across the company’s Pharmaceutical and Diagnostics Divisions and 25,000 employees in 24 sites across eight U.S. states.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Trump to sign executive order aimed at lowering drug prices
- Pharma imports to U.S. surged in March ahead of tariffs, Reuters says
- FDA announces expanded use of unannounced inspections at foreign facilities
- Trump to sign order streamlining U.S. drug manufacturing regulations, WaPo says
- Trump urges drugmakers to accept lower prices on prescriptions, Bloomberg says